Bio-Matrix Scientific Group’s Regen BioPharma subsidiary will use Cook General Biotechnology as its CMO to make clinical supplies of HemaXellerate I. HemaXellerate I is a personalized stem cell treatment that utilizes fat derived cells to inhibit the biological processes responsible for aplastic anemia. The initial batches will be utilized for completing preclinical experiments requested by the FDA for a clinical trial using HemaXellerate I as a therapeutic for treatment resistant aplastic...